In vitro properties of apheresis platelet during extended storage in plasma treated with anandamide

Transfusion and Apheresis Science

Volumn 51, Issue 1, 2014, Pages 58-64

  Zhuang, Yunlong ^a   Ren, Guijie ^b   Li, Huiyu ^c   Tian, Keli ^b   Zhang, Yi ^a   Qiao, Wenben ^a   Nie, Xiangmin ^a   Liu, Yan ^a   Song, Yonghong ^a   Zhu, Chuanfu ^a  

^a Blood Center of Shandong Province   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NANJING AGRICULTURAL UNIVERSITY   (China)

Author keywords

Anandamide; Extended storage; Platelet storage lesions

Indexed keywords

ANANDAMIDE; PADGEM PROTEIN; PHOSPHATIDYLSERINE; AMIDE; ARACHIDONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; ENDOCANNABINOID;

APOPTOSIS; ARTICLE; BACTERIUM CONTAMINATION; BLOOD BANK; BLOOD VOLUME; CARBON DIOXIDE TENSION; CLINICAL EVALUATION; CONTROLLED STUDY; EFFECTIVE CONCENTRATION; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN EXPERIMENT; HYPOTONIC SHOCK RESPONSE; IN VITRO STUDY; NORMAL HUMAN; OXYGEN TENSION; PH; PHYSICAL EXAMINATION; PLATELET DISTRIBUTION WIDTH; PRACTICE GUIDELINE; PROTEIN EXPRESSION; ROOM TEMPERATURE; SHELF LIFE; SHOCK; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; THROMBOCYTE VOLUME; THROMBOCYTOPHERESIS; BLOOD STORAGE; FEMALE; MALE; METABOLISM; PLASMA; PROCEDURES; THROMBOCYTE; TIME;

ARACHIDONIC ACIDS; BLOOD PLATELETS; BLOOD PRESERVATION; CALCIUM CHANNEL BLOCKERS; ENDOCANNABINOIDS; FEMALE; HUMANS; MALE; PLASMA; PLATELETPHERESIS; POLYUNSATURATED ALKAMIDES; TIME FACTORS;

EID: 84930040352     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2014.03.009     Document Type: Article

References (40)

1. Brown S.B., Clarke M.C., Magowan L., Sanderson H., Savill J. Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis. A caspase-independent cell clearance program. J Biol Chem 2000, 275:5987-5996.
2. Cookson P., Sutherland J., Turner C., Bashir S., Wiltshire M., Hancock V., et al. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfus Med 2010, 20:392-402.
3. Catani M.V., Gasperi V., Evangelista D., Finazzi Agrò A., Avigliano L., Maccarrone M. Anandamide extends platelets survival through CB1-dependent Akt signaling. Cell Mol Life Sci 2010, 67:601-610.
4. Mason K.D., Carpinelli M.R., Fletcher J.I., Collinge J.E., Hilton A.A., Ellis S., et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
5. Shrivastava M. The platelet storage lesion. Transfus Apher Sci 2009, 41(2):105-113.
6. Maccarrone M., Bari M., Menichelli A., Del Principe D., Agrò A.F. Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett 1999, 447:277-282.
7. Catani M.V., Gasperi V., Catanzaro G., Baldassarri S., Bertoni A., Sinigaglia F., et al. Human platelets express authentic CB1 and CB2 receptors. Curr Neurovasc Res 2010, 7:311-318.
8. Gómez del Pulgar T., Velasco G., Guzmán M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 2000, 347(Pt2):369-373.
9. Liu J., Gao B., Mirshahi F., Sanyal A.J., Khanolkar A.D., Makriyannis A., et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000, 346(Pt3):835-840.
10. Pestonjamasp V.K., Burstein S.H. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta 1998, 1394(2-3):249-260.
11. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 1997, 390(6659):518-521.
12. AuBuchon J.P. Safer, cheaper and just as good: making sterile, 7-day platelets a reality. 2001 Annual Meeting of the American Association of Blood Banks: technical/scientific compendium 2001, 425-432. American Association of Blood Banks, Bethesda, MD.
13. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008, 14:923-930.
14. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009, 49:123-150.
15. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A 1993, 90(16):7656-7660.
16. Pertwee R.G., Stevenson L.A., Griffin G. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol 1993, 110(4):1483-1490.
17. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 1993, 44(3):498-503.
18. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994, 270(1):219-227.
19. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394(6690):277-281.
20. Mechoulam R., Fride E., Hanus L., Sheskin T., Bisogno T., Di Marzo V., et al. Anandamide may mediate sleep induction. Nature 1997, 389(6646):25-26.
21. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995, 92(8):3376-3380.
22. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., et al. Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca(2+)-dependent transacylase and phosphodiesterase activities. Biochem Biophys Res Commun 1996, 218(1):113-117.
23. Schmid P.C., Paria B.C., Krebsbach R.J., Schmid H.H., Dey S.K. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci U S A 1997, 94(8):4188-4192.
24. Maccarrone M., Finazzi-Agró A. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ 2003, 10(9):946-955.
25. Pushkarev V.M., Kovzun O.I., Tronko M.D. Antineoplastic and apoptotic effects of cannabinoids. N-acylethanolamines: protectors or killers?. Exp Oncol 2008, 30(1):6-21.
26. Signorello M.G., Giacobbe E., Passalacqua M., Leoncini G. The anandamide effect on NO/cGMP pathway in human platelets. J Cell Biochem 2011, 112:924-932.
27. Centonze D., Battistini L., Maccarrone M. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des 2008, 14:2370-2382.
28. Giuffrida A., Piomelli D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett 1998, 422(3):373-376.
29. Wagner J.A., Varga K., Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med (Berl) 1998, 76(12):824-836.
30. Mukhopadhyay S., Chapnick B.M., Howlett A.C. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol 2002, 282(6):H2046-H2054.
31. McCollum L., Howlett A.C., Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor - independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 2007, 321(3):930-937.
32. Cohen Z., Wilson J., Ritter L., McDonagh P. Caspase inhibition decreases both platelet phosphatidylserine exposure and aggregation: caspase inhibition of platelets. Thromb Res 2004, 113(6):387-393.
33. Dasgupta S.K., Argaiz E.R., Mercado J.E., Maul H.O., Garza J., Enriquez A.B., et al. Platelet senescence and phosphatidylserine exposure. Transfusion 2010, 50(10):2167-2175.
34. Vetlesen A., Mirlashari M.R., Torsheim I.A., Kjeldsen-Kragh J. Platelet activation and residual activation potential during storage of hyperconcentrated platelet products in two different platelet additive solutions. Transfusion 2005, 45:1349-1355.
35. Mutlu A., Gyulkhandanyan A.V., Freedman J., Leytin V. Concurrent and separate inside-out transition of platelet apoptosis and activation markers to the platelet surface. Br J Haematol 2013, 163(3):377-384.
36. Holme S., Heaton W.A., Courtright M. Improved in vivo and in vitro viability of platelet concentrates stored for seven days in a platelet additive solution. Br J Haematol 1987, 66(2):233-238.
37. Murphy S., Holme S., Nelson E., Carmen R. Paired comparison of the in vivo and in vitro results of storage of platelet concentrates in two containers. Transfusion 1984, 24(1):31-34.
38. Holme S., Moroff G., Murphy S. A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Transfusion 1998, 38:31-40.
39. AuBuchon J.P., Taylor H., Holme S., Nelson E. In vitro and in vivo evaluation of leukoreduced platelets stored for 7 days in CLX containers. Transfusion 2005, 45(8):1356-1361.
40. Rinder H.M., Smith B.R. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function?. Transfusion 2003, 43(1):2-6.